Epredia

Epredia

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Epredia, a subsidiary of PHC Holdings Corporation, is a commercial-stage company focused on the diagnostics and medical devices sectors, specifically in anatomic pathology. It offers a comprehensive portfolio including tissue processors, slide printers, and the FDA-cleared E1000 Dx Digital Pathology Solution. Founded in 2019, the company operates globally from its U.S. headquarters, serving as a critical infrastructure provider for cancer diagnostic workflows.

Oncology

Technology Platform

Integrated anatomic pathology workflow platform encompassing histology instruments (tissue processors, slide printers), consumables, and FDA-cleared digital pathology solutions (scanners and image management software).

Funding History

1
UndisclosedUndisclosed

Opportunities

The global shift to digital pathology represents a massive upgrade cycle for laboratories, creating demand for integrated scanner and software solutions.
The rising global cancer burden and shortage of pathologists drive the need for more efficient and precise diagnostic tools, expanding the addressable market for Epredia's full workflow portfolio.

Risk Factors

Intense competition from large, established players in both histology and digital pathology could pressure market share and pricing.
The rate of adoption for digital pathology systems is dependent on laboratory capital budgets and regulatory changes, which can be slow and variable across different global regions.

Competitive Landscape

Epredia competes in a crowded market dominated by large corporations like Roche (Ventana), Danaher (Leica Biosystems), and Philips in digital pathology, and Thermo Fisher Scientific and Sakura Finetek in histology. Its strategy is to differentiate through a broad, integrated product portfolio and a legacy of trust in traditional histology to cross-sell digital solutions.